<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02524639</url>
  </required_header>
  <id_info>
    <org_study_id>15-011973</org_study_id>
    <nct_id>NCT02524639</nct_id>
  </id_info>
  <brief_title>Sirolimus for the Treatment of Hyperinsulinism</brief_title>
  <official_title>Pilot Study of the Efficacy and Safety of Sirolimus in the Treatment of Congenital Hyperinsulinism.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital of Philadelphia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pilot study is to generate data to assess feasibility of study&#xD;
      design/procedures and for formal sample size estimation for a larger multicenter study of the&#xD;
      efficacy and safety of sirolimus in infants with medically-unresponsive congenital&#xD;
      hyperinsulinism (HI) due to inactivating mutations of adenosine triphosphate-sensitive&#xD;
      potassium (KATP) channels.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment options for children with diffuse adenosine triphosphate-sensitive potassium (KATP)&#xD;
      channel hyperinsulinism (KATPHI) are limited and most of them require a near-total&#xD;
      pancreatectomy to control the hypoglycemia. However, at least 40% of these children continue&#xD;
      to have persistent hypoglycemia after surgery and their long-term outcomes are complicated by&#xD;
      the development of diabetes.&#xD;
&#xD;
      There is evidence that suggests that mammalian target of rapamycin (mTOR) inhibitors are&#xD;
      useful in controlling the hypoglycemia in hyperinsulinemic hypoglycemia. But before adapting&#xD;
      this as standard therapy for children with hyperinsulinism, a carefully controlled study of&#xD;
      the efficacy and safety of sirolimus for hyperinsulinism is clearly needed.&#xD;
&#xD;
      Sirolimus is an mTOR inhibitor, which is FDA-approved for the prophylaxis of organ rejection&#xD;
      in patients age 13 years and older receiving kidney transplantation. This is an open label&#xD;
      pilot study to assess the effect, safety and tolerability of sirolimus in infants with&#xD;
      diazoxide-unresponsive HI due to mutations in the genes encoding the KATP channels. Subjects&#xD;
      will be treated with sirolimus for 6 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Due to strict inclusion and exclusion criteria no subjects were enrolled&#xD;
  </why_stopped>
  <start_date type="Anticipated">August 12, 2015</start_date>
  <completion_date type="Actual">May 29, 2018</completion_date>
  <primary_completion_date type="Actual">May 29, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of children off intravenous dextrose support</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in number hypoglycemic episodes per child per day</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma insulin levels during fasting</measure>
    <time_frame>8 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse Events</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hyperinsulinism</condition>
  <arm_group>
    <arm_group_label>Sirolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All enrolled subjects will receive Sirolimus 1 mg/m2/day twice a day for 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Subjects will receive 1 mg/m2/day orally for 6 weeks. Maintenance dose will be titrated up or down by 0.25-0.5 mg/m2/day every 4 days. Serum concentration will be checked on day 4 after initial therapy and 4 days after any dose adjustment. Levels will be checked at lease once a week during the duration of the study. Target serum concentration range is 5-10 ng/mL.</description>
    <arm_group_label>Sirolimus</arm_group_label>
    <other_name>Rapamune</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or females age â‰¥14 days to 12 months.&#xD;
&#xD;
          2. Confirmed diagnosis of hyperinsulinism.&#xD;
&#xD;
          3. Mutation analysis results demonstrating bi-allelic mutations in either ABCC8 or&#xD;
             KCNJ11.&#xD;
&#xD;
          4. Failure to respond to maximal dose of diazoxide (15 mg/kg/day), if diazoxide is&#xD;
             indicated.&#xD;
&#xD;
               1. Unable to wean intravenous dextrose after at least 3 days of diazoxide therapy&#xD;
                  and/or&#xD;
&#xD;
               2. Persistent hypoglycemia after at least 3 days of diazoxide therapy&#xD;
&#xD;
          5. High glucose infusion rate requirement (greater or equal to 10 mg/kg/min).&#xD;
&#xD;
          6. Parental/guardian permission (informed consent).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Infants with suspected or confirmed focal hyperinsulinism who are candidates for&#xD;
             surgical resection&#xD;
&#xD;
          2. Current therapy with diazoxide. Subjects may be eligible for participation 48 hrs&#xD;
             after discontinuation of diazoxide.&#xD;
&#xD;
          3. Laboratory abnormalities that indicate clinically significant hematologic,&#xD;
             hepatobiliary, or renal disease:&#xD;
&#xD;
               1. AST/SGOT &gt; 2.5 times the upper limit of normal&#xD;
&#xD;
               2. ALT/SGPT &gt; 2.5 times the upper limit of normal&#xD;
&#xD;
               3. Total bilirubin &gt; 2.5 times the upper limit of normal&#xD;
&#xD;
               4. Hemoglobin &lt; 9 gm/dL&#xD;
&#xD;
               5. White blood cell count &lt; 3,000/ mm3&#xD;
&#xD;
               6. Platelet count &lt; 100,000/mm3&#xD;
&#xD;
               7. Creatinine &gt; 2.5 times the upper limit of normal&#xD;
&#xD;
          4. Evidence of active infection.&#xD;
&#xD;
          5. Evidence of cardiac or respiratory failure.&#xD;
&#xD;
          6. Known immune deficiency.&#xD;
&#xD;
          7. Preterm (&lt; 37 week gestation at birth).&#xD;
&#xD;
          8. Treatment with immunosuppressants.&#xD;
&#xD;
          9. Treatment with any drug known to interact significantly with sirolimus (strong&#xD;
             inducers and strong inhibitors of CYP3A4 and P-gp with risk category D and X)&#xD;
             including:&#xD;
&#xD;
             Cyclosporine, clozapine, conivaptan, crizotinib, dabrafenib, dipyrone, boceprevir,&#xD;
             echinacea, efavirenz, enzalutamide, fluconazole, fosphenytoin, fusidic acid,&#xD;
             idelalisib, leflunomide, lomitapide, mifepristone, mitotane, natalizumab, nelfinavir,&#xD;
             phenytoin, pimecrolimus, pimozide, posaconazole, roflumilast, St Johns Wort,&#xD;
             stiripentol, tacrolimus, telaprevir, tofacitinib, rifampin, rifabutin, ketoconazole,&#xD;
             voriconazole, itraconazole, erythromycin, telithromycin, clarithromycin&#xD;
&#xD;
         10. Any investigational drug use within 5 half-lives of the drug prior to initiation of&#xD;
             therapy.&#xD;
&#xD;
             Subjects who had participated in other investigational drug studies will be eligible&#xD;
             to participate after 5 half-lives from the last dose of the investigational agent and&#xD;
             have recovered from acute investigational agent associated toxicity&#xD;
&#xD;
         11. History of surgical procedure within 8 weeks of enrollment.&#xD;
&#xD;
         12. Parents/guardians or subjects who, in the opinion of the Investigator, may be&#xD;
             non-compliant with study schedules or procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>12 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diva De Leon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>August 12, 2015</study_first_submitted>
  <study_first_submitted_qc>August 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2015</study_first_posted>
  <last_update_submitted>June 12, 2018</last_update_submitted>
  <last_update_submitted_qc>June 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital of Philadelphia</investigator_affiliation>
    <investigator_full_name>Diva De Leon</investigator_full_name>
    <investigator_title>Study Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperinsulinism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

